Departing from industry norms, Curie.Bio intentionally allocates a large equity stake to founders. They see this not just as fair but as a utilitarian strategy to gain a competitive advantage in sourcing the rarest and most valuable scientific ideas, which ultimately drives fund returns.

To solve the critical challenge of hiring expensive, specialized talent, Curie.Bio offers its portfolio companies access to a 100+ person team of elite "drug makers" on a fractional, at-cost basis. This provides world-class expertise on demand without the burden of full-time payroll, de-risking early development.

The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

Beyond accelerators, pure investors, and traditional company builders, this new VC model provides "hardcore primary data generation drug making support." It involves a team of 10+ experts engaging with a startup multiple times per day, offering an intensity of operational involvement that other models lack.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Europe's decentralized biotech ecosystem offers a major operational advantage over hubs like Boston. Lower competition for talent, lab space, and clinical trial sites allows startups to operate at 50% of the cost, coupled with pre-money valuations that are often 40% lower, creating significant capital efficiency.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.